This study will examine the influence of donor and recipient pharmacogenetics (PG), drug
pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy
to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the
graft versus tumor effect, while minimizing acute and chronic graft versus host disease
(GVHD).